Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hauben

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Clinical Therapeutics|January 22, 2021
Artificial Intelligence in Pharmacovigilance: Scoping Points to ConsiderManfred Hauben, Craig G Hartford
International Journal of Medical Sciences|June 27, 2013
Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's conditionManfred Hauben, Eric Y Hung
Therapeutic Advances in Drug Safety|June 15, 2016
Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilanceManfred Hauben, Eric Y Hung
Drug Safety|February 23, 2018
Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational DatabasesEd Whalen, Manfred Hauben, Andrew Bate
Drug Safety|January 27, 2007
Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactionsManfred Hauben, Sebastian Horn, Lester Reich
European Journal of Clinical Pharmacology|December 25, 2004
Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithmsManfred Hauben, Lester Reich, Stephanie Chung
JAMA|March 17, 2005
Evaluation of suspected adverse drug reactionsManfred Hauben, Eugène P van Puijenbroek
Drug Safety|March 10, 2006
Extension of points on clarifying terminology in drug safetyManfred Hauben, Lester Reich, Flic Gabbay
Drug Safety|April 20, 2010
Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluationFrançois Maignen, Manfred Hauben, Panos Tsintis
Clinical Therapeutics|December 15, 2018
Deconstructing the Pharmacovigilance Hype CycleManfred Hauben, Robert Reynolds, Patrick Caubel
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Clinical Therapeutics|January 22, 2021
Artificial Intelligence in Pharmacovigilance: Scoping Points to ConsiderManfred Hauben, Craig G Hartford
International Journal of Medical Sciences|June 27, 2013
Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's conditionManfred Hauben, Eric Y Hung
Therapeutic Advances in Drug Safety|June 15, 2016
Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilanceManfred Hauben, Eric Y Hung
Drug Safety|February 23, 2018
Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational DatabasesEd Whalen, Manfred Hauben, Andrew Bate
Drug Safety|January 27, 2007
Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactionsManfred Hauben, Sebastian Horn, Lester Reich
European Journal of Clinical Pharmacology|December 25, 2004
Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithmsManfred Hauben, Lester Reich, Stephanie Chung
JAMA|March 17, 2005
Evaluation of suspected adverse drug reactionsManfred Hauben, Eugène P van Puijenbroek
Drug Safety|March 10, 2006
Extension of points on clarifying terminology in drug safetyManfred Hauben, Lester Reich, Flic Gabbay
Drug Safety|April 20, 2010
Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluationFrançois Maignen, Manfred Hauben, Panos Tsintis
Clinical Therapeutics|December 15, 2018
Deconstructing the Pharmacovigilance Hype CycleManfred Hauben, Robert Reynolds, Patrick Caubel
Pageof 12